Arcadia Deferred Long Term Liab from 2010 to 2025
| RKDA Stock | USD 3.39 0.08 2.42% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 1.8 M | Current Value 2.1 M | Quarterly Volatility 422.7 K |
Check Arcadia Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcadia Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 501.1 K, Interest Expense of 247.1 K or Selling General Administrative of 14.7 M, as well as many indicators such as Price To Sales Ratio of 1.52, Dividend Yield of 0.0018 or PTB Ratio of 1.36. Arcadia financial statements analysis is a perfect complement when working with Arcadia Biosciences Valuation or Volatility modules.
Arcadia | Deferred Long Term Liab |
Latest Arcadia Biosciences' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Arcadia Biosciences over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Arcadia Biosciences' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcadia Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Arcadia Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 2,373,512 | |
| Geometric Mean | 2,339,195 | |
| Coefficient Of Variation | 17.81 | |
| Mean Deviation | 392,802 | |
| Median | 2,119,000 | |
| Standard Deviation | 422,669 | |
| Sample Variance | 178.6B | |
| Range | 1.3M | |
| R-Value | (0.82) | |
| Mean Square Error | 62.3B | |
| R-Squared | 0.67 | |
| Significance | 0.000096 | |
| Slope | (72,920) | |
| Total Sum of Squares | 2.7T |
Arcadia Deferred Long Term Liab History
About Arcadia Biosciences Financial Statements
Arcadia Biosciences stakeholders use historical fundamental indicators, such as Arcadia Biosciences' Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although Arcadia Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Arcadia Biosciences' assets and liabilities are reflected in the revenues and expenses on Arcadia Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Arcadia Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 1.8 M | 2.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of Arcadia Biosciences Correlation against competitors. For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Agricultural Products & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcadia Biosciences. If investors know Arcadia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcadia Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.285 | Earnings Share (3.17) | Revenue Per Share | Quarterly Revenue Growth 0.565 | Return On Assets |
The market value of Arcadia Biosciences is measured differently than its book value, which is the value of Arcadia that is recorded on the company's balance sheet. Investors also form their own opinion of Arcadia Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcadia Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcadia Biosciences' market value can be influenced by many factors that don't directly affect Arcadia Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcadia Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcadia Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcadia Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.